logo-loader
Health
viewPropanc Biopharma Inc

Propanc Biopharma moves closer to first-in-human study by quantifying ingredients for its metastatic cancer drug

This step allows Propanc to move forward in discussions with potential sites for its clinical trial, which the company expects to launch in early 2020

Cancerous tumor
The company plans to present its findings to the Peter Mac Center, Australia’s largest cancer hospital

Propanc Biopharma Inc (OTCMKTS:PPCB) is gearing up for a first-in-human trial of its metastatic cancer treatment, and has just completed a crucial step: quantifying the active ingredients.

The drug candidate, PRP is a mix of two proenzymes that targets solid cancerous tumors. The Melbourne-based company’s research partner in Berlin has developed a highly sensitive technique for measuring the ratios of the proenzymes as well as the two enzymes it activates. 

This step is crucial in developing the drug at scale and determining dosing, and its completion allows Propanc to move forward in discussions with potential sites for its clinical trial, which the company expects to launch in early 2020.

READ: Propanc Biopharma gears up to file clinical trial application for its lead anti-cancer therapy PRP

The company plans to present its findings to the Peter Mac Center, Australia’s largest cancer hospital, in what’s known as the pre-validation phase. 

“This is an important step for the advancement of PRP towards commencing our first-in-human study,” Propanc's Chief Scientific Officer Julian Kenyon said in a statement. 

“Understanding clinical effects and their relationship to the concentration of the drug over time is especially important so that we can optimize dosing of PRP when administered to patients,” he added.

Traders responded optimistically, driving shares 22% higher to $1.70 Thursday afternoon.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Propanc Biopharma Inc

Price: 0.9 USD

OTCMKTS:PPCB
Market: OTCMKTS
Market Cap: $1.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Voyager Digital begins trading on the Canadian Securities...

Voyager Digital (CSE: VYGR) CEO Stephen Ehrlich joined Steve Darling from Proactive in Toronto to discuss the crypto company now listed on the CSE under the ticker VYGR.  Erhlich, who rang the opening bell of the CSE talks about the company, their token, and how they feel their...

18 hours, 56 minutes ago

2 min read